MedTrace Logo

Trial of Rifaximin in the Treatment of Tropical Enteropathy

NCT00858988 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2019-11-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether rifaximin is effective in the treatment of tropical enteropathy in a population of African children at high risk for this disease.

Conditions

  • Tropical Enteropathy

Interventions

DRUG

Rifaximin

100mg of rifaxin for 7 consecutive days, twice daily

DRUG

Placebo

twice daily for 7 consecutive days

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • Kamuzu University of Health Sciences

    collaborator OTHER

  • United States Department of Agriculture (USDA)

    collaborator FED

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Mark J Manary · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • Malawi

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00858988 on ClinicalTrials.gov